M. Faye Wilson, CPA, MBA
Lead Independent Director and Interim Chair
Ms. Wilson is the chair of Biocept’s audit committee and also serves as our Interim Chair. She has been a principal and President of Wilson Boyles & Co., LLC, a business management and strategic planning consulting firm, since 2003. Ms. Wilson also serves currently as a member of the board of directors of IQHQ, a real estate investment trust and is a board member of Sharp Health Care Systems. She has served on the board of directors of Biomed Realty Trust, Inc., Farmers Insurance Group of Companies and The Home Depot, Inc. Ms. Wilson was also a senior officer of Home Depot from 1998 through 2002. From 1992 until 1998, Ms. Wilson served in several senior management roles at Bank of America Corporation including Chairman of Security Pacific Financial Services and Executive Vice President of Bank of America.
David F. Hale
Mr. Hale is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences technology companies.
Mr. Hale was selected to serve on and lead the board of directors due to his public and private company board experience as well as his extensive knowledge of health care issues and the operational activities of life sciences companies.
Michael W. Nall
President and Chief Executive Officer
Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010.
Mr. Nall was selected to serve on the board of directors due to his experience in the cancer diagnostics business, his expertise in the commercialization of products and services such as Biocept’s, his background in reimbursement and operations and his status as the company’s chief executive officer and president.
Marsha A. Chandler Ph.D.
Science and Technology Committee
Dr. Chandler is a member of Biocept’s science and technology committee. She has been the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007 where she manages approximately 1,000 scientific and administrative personnel, and oversees all institutional fiscal, administrative and fund-raising activities. From 1997 to 2007 she served as Senior Vice Chancellor for Academic Affairs at the University of California, San Diego, where she was the chief academic officer responsible for the policies and decisions relating to all academic programs and faculty appointments and performance.
Bruce E. Gerhardt, CPA
Mr. Gerhardt is a member of Biocept’s audit committee. He has been self-employed, practicing as a Certified Public Accountant, since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. Gerhardt earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants.
Ivor Royston M.D.
Science and Technology Committee
Dr. Royston is the chair of Biocept’s science and technology committee. He co-founded Forward Ventures and has served as its Managing Partner since 2000. From 1990 to 2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was a member of the oncology faculty of the University of California, San Diego. In addition to being a co-founder of Hybritech, Inc., in 1986 he co-founded IDEC Corporation, which later merged with Biogen to form BiogenIdec.
Samuel D. Riccitelli
Science and Technology and Audit Committees
Samuel D. Riccitelli has served as a member of the Board of Directors of Orthopediatrics, Inc. (Nasdaq: KIDS) since 2017, a company focused exclusively on the orthopedic implant needs of children. He recently served as Chief Executive Officer of Pathnostics, LLC, a molecular diagnostics company focused on improving antibiotic stewardship, from 2019 to 2020. From 2017 to 2019, Mr. Riccitelli served as Chairman of the Board of Directors of Precipio, Inc. (Nasdaq: PRPO), a diagnostic services company. From 2012 to 2017, Mr. Riccitelli served as President and Chief Executive Officer and a Director of Signal Genetics, Inc., a publicly traded molecular diagnostic company that was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic company that was sold to Novartis in 2011. Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, as a vice president and general manager and as a board member for BD Ventures, LLC., a venture capital fund. Mr. Riccitelli received a B.A. from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas.